Page 5 - Kineta Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Focus on Biotech Stocks: (NASDAQ: CRDL) (NASDAQ: KA) (TSXV: MDCX) (OTCQB: SKYE)

Focus on Biotech Stocks: (NASDAQ: CRDL) (NASDAQ: KA) (TSXV: MDCX) (OTCQB: SKYE)

United statesBrightspring health services incSkinject incNeurobo pharmaceuticals incKineta incSkye bioscience incBiotech life sciences directoriesOncolytics biotech incLife sciences incCardiol therapeutics incMedicus pharma ltdAinos incStocks addedLife sciences directoriesLife sciencesMetabolic dysfunction associated steatohepatitis

Kineta to Participate in H C Wainwright Virtual @Home Fireside Chat Series

Kineta to Participate in H C Wainwright Virtual @Home Fireside Chat Series
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert burnsShawn iadonatoThierry guillaudeuxBruce macklelifesci advisorsJacques bouchyevp investor relations business developmentKineta incHome fireside chat seriesChief executive officerChief scientific officerFireside chathostManaging directorSenior healthcare analystregistrationStatements regarding forward lookingPrivate securities litigation reform actAnnual reportQuarterly reports

KVA12123 Showcases Early Tolerability in Advanced Solid Tumors

KVA12123 demonstrated early signals of on-target activity and tolerability at all dose levels examined to date in patients with advanced solid tumors.

Thierry guillaudeuxShawn iadonatoKineta incAdvanced solid tumorsPhase 1 2 vista 101 trialKva12123 plus pembrolizumabKva12123 monotherapy

Chemotherapy Induced Peripheral Neuropathy Treatment Market

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) The

United statesSolasia pharmaAsahi kasei pharma corporationAphios corporationJazz pharmaceuticals incPharmaceuticals incNemus bioscience incAmgen incAbbott laboratoriesQuidel corporationKrenitsky pharmaceuticals incGenentech incKineta incChromadex corpToray industriesBiosciences inc

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesShawn iadonatoThierry guillaudeuxBruce macklelifesci advisorsMerck co incMerck sharp dohmeJacques bouchyevp investor relations business developmentKineta incInitial combination cohortDemonstrated dose proportional inductionPro inflammatory biomarkers requiredStrong anti tumorInitial combination clinical data anticipatedChief executive officerReceptor occupancyChief scientific officer